The amino acid transporter SLC7A11 expression in breast cancer

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–14. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013;32(5):617–628. doi:10.1038/emboj.2013.19.
   PubMed Web of Science ®Google Scholar
• Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014;11(1):1–19. doi:10.7497/j.issn.2095-3941.2014.01.001.
   PubMedGoogle Scholar
• Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. 2020. Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front Oncol. 10:589508. doi:10.3389/fonc.2020.589508.
   PubMed Web of Science ®Google Scholar
• Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol. 2020;98:34–43. doi:10.1016/j.semcdb.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Choi Y-K, Park K-G. Targeting glutamine metabolism for cancer treatment. Biomol & Therapeutics. 2018;26(1):19. doi:10.4062/biomolther.2017.178.
   PubMed Web of Science ®Google Scholar
• Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M. The cystine/glutamate antiporter system xc− in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18(5):522–555. doi:10.1089/ars.2011.4391.
   PubMed Web of Science ®Google Scholar
• Chio IIC, Tuveson DA. Ros in cancer: the burning question. Trends Mol Med. 2017;23(5):411–429. doi:10.1016/j.molmed.2017.03.004.
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhuang L, Gan B. Cystine transporter slc7a11/xct in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599–620. doi:10.1007/s13238-020-00789-5.
   PubMed Web of Science ®Google Scholar
• Zhu J, Berisa M, Schwörer S, Qin W, Cross JR, Thompson CB. Transsulfuration activity can support cell growth upon extracellular cysteine limitation. Cell Metab. 2019;30(5):865–876. e865. doi:10.1016/j.cmet.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Wei Z, Liu X, Cheng C, Yu W, Yi P. 2021. Metabolism of amino acids in cancer. Front Cell Dev Biol. 8:603837. doi:10.3389/fcell.2020.603837.
   PubMed Web of Science ®Google Scholar
• Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter slc7a11/xct at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38(1):1–13. doi:10.1186/s40880-018-0288-x.
   Google Scholar
• Lu SC. Glutathione synthesis. Biochimica et Biophysica Acta (BBA)-general subjects. Biochim et Biophys Acta (BBA) - Gen Subj. 2013;1830(5):3143–3153. doi:10.1016/j.bbagen.2012.09.008.
   PubMed Web of Science ®Google Scholar
• Combs JA, DeNicola GM. The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. Cancers. 2019;11(5):678. doi:10.3390/cancers11050678.
   PubMed Web of Science ®Google Scholar
• Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H. Suppression of the slc7a11/glutathione axis causes synthetic lethality in kras-mutant lung adenocarcinoma. J Clin Invest. 2020;130(4):1752–1766. doi:10.1172/JCI124049.
   PubMed Web of Science ®Google Scholar
• Ji X, Qian J, Rahman SJ, Siska PJ, Zou Y, Harris BK, Hoeksema MD, Trenary IA, Heidi C, Eisenberg R. Xct (slc7a11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene. 2018;37(36):5007–5019. doi:10.1038/s41388-018-0307-z.
   PubMed Web of Science ®Google Scholar
• Lin W, Wang C, Liu G, Bi C, Wang X, Zhou Q, Jin H. 2020. Slc7a11/xct in cancer: biological functions and therapeutic implications. Am J Cancer Res. 10:3106.
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhang H, Lian M, Yue C, Dong G, Jin Y, Li R, Wan H, Wang R, Wang Y, et al. Slc7a11, a component of cysteine/glutamate transporter, is a novel biomarker for the diagnosis and prognosis in laryngeal squamous cell carcinoma. Oncol Rep. 2017;38(5):3019–3029. doi:10.3892/or.2017.5976.
   PubMed Web of Science ®Google Scholar
• Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM. Slc7a11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015;7(289):289ra286–289ra286. doi:10.1126/scitranslmed.aaa8103.
   Web of Science ®Google Scholar
• Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyüpoglu IY. Small interfering rna–mediated xct silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med. 2008;14(6):629–632. doi:10.1038/nm1772.
   PubMed Web of Science ®Google Scholar
• Sharbeen G, McCarroll JA, Akerman A, Kopecky C, Youkhana J, Kokkinos J, Holst J, Boyer C, Erkan M, Goldstein D. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to slc7a11 inhibition. Cancer Res. 2021;81(13):3461–3479. doi:10.1158/0008-5472.CAN-20-2496.
   PubMed Web of Science ®Google Scholar
• Zhang L, Huang Y, Ling J, Zhuo W, Yu Z, Luo Y, Zhu Y. Overexpression of slc7a11: A novel oncogene and an indicator of unfavorable prognosis for liver carcinoma. Future Oncol. 2018;14(10):927–936. doi:10.2217/fon-2017-0540.
   PubMed Web of Science ®Google Scholar
• Zhu JH, De Mello RA, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ, Tang HJ, Huang T. Mir-139-5p/slc7a11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via pi3k/akt signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2020;1866(6):165747. doi:10.1016/j.bbadis.2020.165747.
   PubMed Web of Science ®Google Scholar
• Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S. Immunotargeting of antigen xct attenuates stem-like cell behavior and metastatic progression in breast cancer. Cancer Res. 2016;76(1):62–72. doi:10.1158/0008-5472.CAN-15-1208.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP. Functional interactions of the cystine/glutamate antiporter, cd44v and muc1-c oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016;7(11):11756. doi:10.18632/oncotarget.7598.
   PubMedGoogle Scholar
• Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, Van‘t Veer LJ. Glutamine sensitivity analysis identifies the xct antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013;24(4):450–465. doi:10.1016/j.ccr.2013.08.020.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim DH, Jung W-H, Koo JS. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013;20(3):339–348. doi:10.1530/ERC-12-0398.
   PubMed Web of Science ®Google Scholar
• Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z. Crosstalk between estrogen signaling and breast cancer metabolism. Trends In Endocrinol Metabolism. 2019;30(1):25–38. doi:10.1016/j.tem.2018.10.006.
   PubMed Web of Science ®Google Scholar
• Gong Y, Ji P, Yang Y-S, Xie S, Yu T-J, Xiao Y, Jin M-L, Ma D, Guo L-W, Pei Y-C. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(1):51–64. e59. doi:10.1016/j.cmet.2020.10.012.
   PubMed Web of Science ®Google Scholar
• Verschoor ML, Singh G. Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer. Mol Cancer. 2013;12(1):138. doi:10.1186/1476-4598-12-138.
   PubMedGoogle Scholar
• Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62. doi:10.1038/nature14344.
   PubMed Web of Science ®Google Scholar
• Bhutia YD, Ganapathy V. Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta. 2016;1863(10):2531–2539. doi:10.1016/j.bbamcr.2015.12.017.
   PubMed Web of Science ®Google Scholar
• Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by cd44 variant isoforms. Oncogene. 2013;32(44):5191–5198. doi:10.1038/onc.2012.638.
   PubMed Web of Science ®Google Scholar
• Kimbung S, Johansson I, Danielsson A, Veerla S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E. Transcriptional profiling of breast cancer metastases identifies liver metastasis–selective genes associated with adverse outcome in luminal a primary breast cancer. Clin Cancer Res. 2016;22(1):146–157. doi:10.1158/1078-0432.CCR-15-0487.
   PubMed Web of Science ®Google Scholar
• Ge C, Cao B, Feng D, Zhou F, Zhang J, Yang N, Feng S, Wang G, Aa J. The down-regulation of slc7a11 enhances ros induced p-gp over-expression and drug resistance in mcf-7 breast cancer cells. Sci Rep. 2017;7(1):3791. doi:10.1038/s41598-017-03881-9.
   PubMedGoogle Scholar
• Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, Bullen JW, Semenza GL. Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A. 2015;112(33):E4600–4609. doi:10.1073/pnas.1513433112.
   PubMed Web of Science ®Google Scholar
• Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. Increased expression of system xc− in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol Cancer Res. 2016;14(12):1229–1242. doi:10.1158/1541-7786.MCR-16-0028.
   PubMed Web of Science ®Google Scholar
• Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. EMBO Rep. 2016;17(10):1374–1395. doi:10.15252/embr.201642195.
   PubMed Web of Science ®Google Scholar
• Wolf IM, Fan Z, Rauh M, Seufert S, Hore N, Buchfelder M, Savaskan NE, Eyüpoglu IY. Histone deacetylases inhibition by saha/vorinostat normalizes the glioma microenvironment via xct equilibration. Sci Rep. 2014;4(1):6226. doi:10.1038/srep06226.
   PubMedGoogle Scholar
• Ye P, Mimura J, Okada T, Sato H, Liu T, Maruyama A, Ohyama C, Itoh K. Nrf2- and atf4-dependent upregulation of xct modulates the sensitivity of t24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34(18):3421–3434. doi:10.1128/mcb.00221-14.
   PubMed Web of Science ®Google Scholar
• Chen D, Fan Z, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N. Atf4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xct-dependent manner. Oncogene. 2017;36(40):5593–5608. doi:10.1038/onc.2017.146.
   PubMed Web of Science ®Google Scholar
• Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N. The oxido-metabolic driver atf4 enhances temozolamide chemo-resistance in human gliomas. Oncotarget. 2017;8(31):51164–51176. doi:10.18632/oncotarget.17737.
   PubMedGoogle Scholar
• Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase otub1 mediates ferroptosis via stabilization of slc7a11. Cancer Res. 2019;79(8):1913–1924. doi:10.1158/0008-5472.can-18-3037.
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H. Cd44 variant regulates redox status in cancer cells by stabilizing the xct subunit of system xc− and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400. doi:10.1016/j.ccr.2011.01.038.
   PubMed Web of Science ®Google Scholar
• Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T. High expression of cd 44v9 and xct in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine. Cancer Sci. 2018;109(9):2801–2810. doi:10.1111/cas.13728.
   PubMed Web of Science ®Google Scholar
• Ju H-Q, Lu Y-X, Chen D-L, Tian T, Mo H-Y, Wei X-L, Liao J-W, Wang F, Zeng Z-L, Pelicano H. Redox regulation of stem-like cells though the cd44v-xct axis in colorectal cancer: mechanisms and therapeutic implications. Theranostics. 2016;6(8):1160. doi:10.7150/thno.14848.
   PubMed Web of Science ®Google Scholar
• Fairweather SJ, Shah N, Brӧer S.Heteromeric solute carriers: function, structure, pathology and pharmacology.Protein Reviews. 21. 2021:13–127. doi:10.1007/5584_2020_584.
   Google Scholar
• Fotiadis D, Kanai Y, Palacín M. The slc3 and slc7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–158. doi:10.1016/j.mam.2012.10.007.
   PubMed Web of Science ®Google Scholar
• Kandasamy P, Gyimesi G, Kanai Y, Hediger MA. Amino acid transporters revisited: new views in health and disease. Trends Biochem Sci. 2018;43(10):752–789. doi:10.1016/j.tibs.2018.05.003.
   PubMed Web of Science ®Google Scholar
• Shin C-S, Mishra P, Watrous JD, Carelli V, D’Aurelio M, Jain M, Chan DC. The glutamate/cystine xct antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat Commun. 2017;8(1):1–11. doi:10.1038/ncomms15074.
   PubMedGoogle Scholar
• Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, et al. Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat Commun. 2017;8(1):14844. doi:10.1038/ncomms14844.
   PubMedGoogle Scholar
• Muir A, Danai LV, Gui DY, Waingarten CY, Lewis CA, Vander Heiden MG. 2017. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. eLife. 6. doi:10.7554/eLife.27713
   Web of Science ®Google Scholar
• Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, Murtie J, Deng G, Barberis C, Hoffmann D, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mtor inhibition. PLoS ONE. 2017;12(9):e0185092. doi:10.1371/journal.pone.0185092.
   PubMed Web of Science ®Google Scholar
• Fumagalli C, Ranghiero A, Gandini S, Corso F, Taormina S, De Camilli E, Rappa A, Vacirca D, Viale G, Guerini-Rocco E. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. Breast Cancer Res. 2020;22(1):1–11. doi:10.1186/s13058-020-01345-z.
   Web of Science ®Google Scholar
• Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, et al. Myc oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci USA. 2015;112(21):6539–6544. doi:10.1073/pnas.1507228112.
   PubMed Web of Science ®Google Scholar
• Li Y, Li N, Shi J, Ahmed T, Liu H, Guo J, Tang W, Guo Y, Zhang Q. 2019. Involvement of glutathione depletion in selective cytotoxicity of oridonin to p53-mutant esophageal squamous carcinoma cells. Front Oncol. 9:1525. doi:10.3389/fonc.2019.01525.
   PubMed Web of Science ®Google Scholar
• Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493(7433):542–546. doi:10.1038/nature11743.
   PubMed Web of Science ®Google Scholar
• Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi N, et al. Prognostic significance of amino-acid transporter expression (lat1, asct2, and xct) in surgically resected tongue cancer. Br J Cancer. 2014;110(10):2506–2513. doi:10.1038/bjc.2014.178.
   PubMed Web of Science ®Google Scholar
• Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers Basel. 2021;13(17):4455. doi:10.3390/cancers13174455.
   PubMed Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C Neutrophils in cancer: two sides of the same coin. J Immunol res. 2015.
   PubMed Web of Science ®Google Scholar
• Nagasaki T, Schuyler AJ, Zhao J, Samovich SN, Yamada K, Deng Y, Ginebaugh SP, Christenson SA, Woodruff PG, Fahy JV. 15lo1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation. J Clin Invest. 2022;132(1):132. doi:10.1172/JCI151685.
   Web of Science ®Google Scholar
• Yang Y, Wang Y, Guo L, Gao W, Tang T-L, Yan M. Interaction between macrophages and ferroptosis. Cell Death Disease. 2022;13(4):355. doi:10.1038/s41419-022-04775-z.
   PubMed Web of Science ®Google Scholar
• Goodall GJ, Wickramasinghe VO. Rna in cancer. Nat Rev Cancer. 2021;21(1):22–36. doi:10.1038/s41568-020-00306-0.
   PubMed Web of Science ®Google Scholar
• Itai Y, Rappoport N, Shamir R. Integration of gene expression and DNA methylation data across different experiments. Nucleic Acids Res. 2023;51(15):7762–7776. doi:10.1093/nar/gkad566.
   PubMedGoogle Scholar
• Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, Shi J. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020;5(1):213. doi:10.1038/s41392-020-00315-3.
   PubMed Web of Science ®Google Scholar
• Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding rnas and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118. doi:10.1038/s41580-020-00315-9.
   PubMed Web of Science ®Google Scholar
• Alla AS. Transcription factor trapping by RNA in gene regulatory elements. Science. 2015;350:978–981. doi:10.1126/science.aad3346.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, XS L. Timer: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307.
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. 2018. Methsurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 10:277–288. doi:10.2217/epi-2017-0118.
   PubMed Web of Science ®Google Scholar
• Green A, Powe D, Rakha E, Soria D, Lemetre C, Nolan C, Barros F, Macmillan R, Garibaldi J, Ball G. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer. 2013;109(7):1886–1894. doi:10.1038/bjc.2013.528.
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Lab Invest. 2018;98(7):844–855. doi:10.1038/s41374-018-0057-0.
   PubMed Web of Science ®Google Scholar
• Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, et al. Myc functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer. 2016;114(8):917–928. doi:10.1038/bjc.2016.46.
   PubMed Web of Science ®Google Scholar
• Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, et al. Glutamate dehydrogenase (glud1) expression in breast cancer. Breast Cancer Res Treat. 2019;174(1):79–91. doi:10.1007/s10549-018-5060-z.
   PubMed Web of Science ®Google Scholar
• El Ansari R, Alfarsi L, Craze ML, Masisi BK, Ellis IO, Rakha EA, Green AR. The solute carrier slc7a8 is a marker of favourable prognosis in er-positive low proliferative invasive breast cancer. Breast Cancer Res Treat. 2020;181(1):1–12. doi:10.1007/s10549-020-05586-6.
   PubMed Web of Science ®Google Scholar
• El Ansari R, Craze ML, Miligy I, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR. The amino acid transporter slc7a5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal b tumours. Breast Cancer Res. 2018;20(1):21. doi:10.1186/s13058-018-0946-6.
   PubMedGoogle Scholar
• Morotti M, Zois CE, El-Ansari R, Craze ML, Rakha EA, Fan SJ, Valli A, Haider S, Goberdhan DCI, Green AR, et al. Increased expression of glutamine transporter snat2/slc38a2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. Br J Cancer. 2020;124(2):10.1038/s41416-020-01113–y. doi:10.1038/s41416-020-01113-y.
   PubMed Web of Science ®Google Scholar
• Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–410. 2002;41: 151-152, discussion 152-153. doi:10.1111/j.1365-2559.1991.tb00229.x.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F. Primary breast cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v8–30. doi:10.1093/annonc/mdv298.
   PubMed Web of Science ®Google Scholar